{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:40:59Z","timestamp":1792806059242,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.7759\/cureus.98824","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:37:01Z","timestamp":1765309021000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of Long-Term Glucocorticoid Therapy on the Response to Biologic Agents in Rheumatoid Arthritis: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Mahamadou","family":"Sagara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Majjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Toufik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bezza","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Rheumatoid arthritis","author":"Chauhan K","year":"2025","unstructured":"Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid arthritis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/pl00012390","article-title":"What can we learn from the synovium in early rheumatoid arthritis?","volume":"51","author":"Katrib A","year":"2002","unstructured":"Katrib A, McNeil HP, Youssef PP. What can we learn from the synovium in early rheumatoid arthritis?. Inflamm Res. 2002, 51:170-5. 10.1007\/pl00012390","journal-title":"Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala C","year":"2014","unstructured":"Gaujoux-Viala C, Gossec L, Cantagrel A, et al.. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine. 2014, 81:287-97. 10.1016\/j.jbspin.2014.05.002","journal-title":"Joint Bone Spine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27860","article-title":"Strategies toward rheumatoid arthritis therapy; the old and the new","volume":"234","author":"Abbasi M","year":"2019","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019, 234:10018-31. 10.1002\/jcp.27860","journal-title":"J Cell Physiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis","volume":"5","author":"Ogata A","year":"2012","unstructured":"Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2012, 5:27-42. 10.4137\/CMAMD.S7371","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor PC","year":"2019","unstructured":"Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019, 58:i17-26. 10.1093\/rheumatology\/key225","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al.. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021, 73:924-39. 10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra SA","year":"2023","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A, et al.. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023, 82:81-94. 10.1136\/ard-2022-223358","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: current status and future studies","volume":"6","author":"Hua C","year":"2020","unstructured":"Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020, 6:e000536. 10.1136\/rmdopen-2017-000536","journal-title":"RMD Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2153-7","article-title":"Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?","volume":"32","author":"El Zorkany B","year":"2013","unstructured":"El Zorkany B, Alwahshi HA, Hammoudeh M, et al.. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?. Clin Rheumatol. 2013, 32:151-9. 10.1007\/s10067-012-2153-7","journal-title":"Clin Rheumatol"},{"key":"ref11","article-title":"Corticosteroid adverse effects","author":"Yasir M","year":"2025","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182664","article-title":"Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease","volume":"9","author":"Sato AY","year":"2024","unstructured":"Sato AY, Cregor M, McAndrews K, et al.. Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease. JCI Insight. 2024, 9:182664. 10.1172\/jci.insight.182664","journal-title":"JCI Insight"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.03.058","article-title":"The role of the glucocorticoid receptor in inflammation and immunity","volume":"120","author":"Baschant U","year":"2010","unstructured":"Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010, 120:69-75. 10.1016\/j.jsbmb.2010.03.058","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10 Suppl 2","author":"Brattsand R","year":"1996","unstructured":"Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996, 10 Suppl 2:81-90; discussion 91-2. 10.1046\/j.1365-2036.1996.22164025.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes IB","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017, 389:2328-37. 10.1016\/S0140-6736(17)31472-1","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1505615","article-title":"High cumulative glucocorticoid dose is associated with increased levels of inflammation-related mediators in active rheumatoid arthritis","volume":"15","author":"Petrackova A","year":"2024","unstructured":"Petrackova A, Horak P, Savara J, Skacelova M, Kriegova E. High cumulative glucocorticoid dose is associated with increased levels of inflammation-related mediators in active rheumatoid arthritis. Front Immunol. 2024, 15:1505615. 10.3389\/fimmu.2024.1505615","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead088","article-title":"Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis","volume":"62","author":"Palmowski A","year":"2023","unstructured":"Palmowski A, Nielsen SM, Boyadzhieva Z, et al.. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2023, 62:2652-60. 10.1093\/rheumatology\/kead088","journal-title":"Rheumatology (Oxford)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo ML","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-8. 10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen J","year":"2009","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009, 35:745-57, vii-viii. 10.1016\/j.rdc.2009.10.001","journal-title":"Rheum Dis Clin North Am"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821565116","article-title":"TNF-\u03b1 inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile","volume":"116","author":"Dendoncker K","year":"2019","unstructured":"Dendoncker K, Timmermans S, Vandewalle J, et al.. TNF-\u03b1 inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile. Proc Natl Acad Sci U S A. 2019, 116:12942-51. 10.1073\/pnas.1821565116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor PC","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al.. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017, 376:652-62. 10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1362","article-title":"Saving glucocorticoids after rituximab treatment in patients with rheumatoid arthritis: analysis of a common clinical practice cohort","volume":"80","author":"Jurado Quijano G","year":"2021","unstructured":"Jurado Quijano G, Fern\u00e1ndez de la Fuente Burs\u00f3n L, Hern\u00e1ndez-Cruz B, et al.. Saving glucocorticoids after rituximab treatment in patients with rheumatoid arthritis: analysis of a common clinical practice cohort. Ann Rheum Dis. 2021, 80:1132-3. 10.1136\/annrheumdis-2021-eular.1362","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet L","year":"2007","unstructured":"Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007, 30:861-81. 10.2165\/00002018-200730100-00005","journal-title":"Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi EJ","year":"2022","unstructured":"Koshi EJ, Young K, Mostales JC, Vo KB, Burgess LP. Complications of corticosteroid therapy: a comprehensive literature review. J Pharm Technol. 2022, 38:360-7. 10.1177\/87551225221116266","journal-title":"J Pharm Technol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/436605-impact-of-long-term-glucocorticoid-therapy-on-the-response-to-biologic-agents-in-rheumatoid-arthritis-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:37:01Z","timestamp":1765309021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/436605-impact-of-long-term-glucocorticoid-therapy-on-the-response-to-biologic-agents-in-rheumatoid-arthritis-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.98824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}